Opioid Addiction Risk Transparency Act

Bill: 115-s-1049
Sponsor: full_name: Sen. Hassan, Margaret Wood [D-NH]
Introduced: 2017-05-04
Policy area: Health
Subjects: Drug safety, medical device, and laboratory regulation

Drug therapy

Health personnel
Latest action: action_date: 2017-05-04
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2017-05-04
action_desc: Introduced in Senate
text: <p><b>Opioid Addiction Risk Transparency Act</b></p> This bill amends the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration to require a communication plan that is part of a medication's risk evaluation and mitigation strategy to include informing health care providers about the meaning of terms related to properties of the medication described in the labeling.

tv_txt: II 115th CONGRESS 1st Session S. 1049 IN THE SENATE OF THE UNITED STATES May 4, 2017 Ms. Hassan (for herself and Mr. Young ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To allow the Secretary of Health and Human Services to require that risk evaluation and mitigation strategies for certain drugs include communication plans that provide information about drug formulations or properties described in the drug labeling.

1. Short title This Act may be cited as the Opioid Addiction Risk Transparency Act . 2. REMS communication plans Section 505–1(e)(3) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355–1(e)(3) ) is amended— (1) in subparagraph (B), by striking ; or ; (2) in subparagraph (C), by striking the period and inserting ; or ; and (3) by adding at the end the following: (D) disseminating information to health care providers about the meaning of terms related to drug formulations or properties that are described in the drug labeling, including information about the limitations or patient care implications of such formulations or properties, and how such formulations or properties may be related to serious adverse drug events associated with use of the drug. .